CHARACTERIZATION OF HYPOTHALAMIC NA+ TRANSPORT INHIBITOR

下丘脑 NA 转运抑制剂的特性

• 批准号: 3345504
• 负责人: Garner Tripp Haupert
• 金额: $ 18.59万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-09-30 至 1987-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3345504
• 关键词: adenosinetriphosphatase; affinity chromatography; atomic absorption spectrometry; biological products; chemical binding; chemical structure function; erythrocytes; flame photometry; gel filtration chromatography; high performance liquid chromatography; human tissue; hypertension; ion exchange chromatography; ion transport; mass spectrometry; membrane permeability; radiotracer; scintillation counter; ultraviolet spectrometry

Recent studies have suggested that the hypothalamus may play a central role in the development and maintenance of certain forms of experimental hypertension. Plasma from volume-expanded hypertensive animals and patients with essential hypertension has been reported to contain a substance which inhibits (Na,K)ATPase. Sodium pump suppression in vascular smooth muscle caused by such a circulating factor could result in tonic increases in vascular tone, increased vascular sensitivity to vasoactive agents, and arterial hypertension. In certain of the animal models of hypertension it appears that an intact hypothalamus is required for the expression of the sodium-pump suppressing activity. Bovine hypothalamus contains a acid-stable low molecular weight substance which is a potent, reversible inhibitor of the mammalian (Na,K)ATPase, and possesses the characteristics of the putative natriuretic hormone. This factor may be a chemical mediator linking kidney, brain, and the cardiovascular system in the genesis of experimental volume-expanded and certain forms of human essential hypertension. The aims of this proposal are: (1) To obtain reliable assays of the inhibitory factor based on Mg2+ dependent reversible inhibition of purified (Na,K)ATPase, and inhibition of ouabain-sensitive 86Rb+ uptake in human erythrocytes; (2) To use the assays to facilitate purification of the inhibitor by high performance liquid chromatography, affinity chromatography, and chemical manipulation of the molecule; and (3) To determine the chemical nature of the purified inhibitor. Success in the project would make possible direct physiological testing to confirm the inhibitor's role in hypertensive disease as well as in other disorders of altered sodium metabolism and membrane transport phenomena.

最近的研究表明，下丘脑可能发挥了核心作用， 在开发和维护某些形式的实验 高血压 来自体积扩张的高血压动物的血浆， 据报道，患有原发性高血压的患者含有 抑制（Na，K）ATP酶的物质。 血管内钠泵抑制 由这种循环因素引起的平滑肌可能导致强直性 血管张力增加，血管对血管活性物质的敏感性增加 药物和动脉高血压。 在某些动物模型中， 高血压似乎需要一个完整的下丘脑， 钠泵抑制活性的表达。 牛下丘脑 含有酸稳定的低分子量物质， 哺乳动物（Na，K）ATP酶的可逆抑制剂，并具有 假定的利钠激素的特征。 这个因素可能是一个 连接肾脏、大脑和心血管系统的化学介质， 实验性的体积扩大和某些形式的人类的起源 原发性高血压 本提案的目的是：（1）获得 基于Mg 2+依赖性可逆性的抑制因子的可靠测定 纯化的（Na，K）ATP酶的抑制和哇巴因敏感的 人红细胞对~（86）Rb ~+的摄取;（2）利用该方法， 通过高效液相色谱纯化抑制剂， 亲和层析和分子的化学操作;和（3） 确定纯化抑制剂的化学性质。 成功 该项目将使直接的生理测试成为可能， 抑制剂在高血压疾病以及其他 改变钠代谢和膜转运现象。